|
1
|
Bhatt JR and Finelli A: Landmarks in the
diagnosis and treatment of renal cell carcinoma. Nat Rev Urol.
11:517–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Martinez-Salamanca JI, Huang WC, Millan I,
Bertini R, Bianco FJ, Carballido JA, Ciancio G, Hernández C,
Herranz F, Haferkamp A, et al: Prognostic impact of the 2009
UICC/AJCC TNM staging system for renal cell carcinoma with venous
extension. Eur Urol. 59:120–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen KS and DeLuca HF: Isolation and
characterization of a novel cDNA from HL-60 cells treated with
1,25-dihydroxyvitamin D-3. Biochim Biophys Acta. 1219:26–32. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nishiyama A, Matsui M, Iwata S, Hirota K,
Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y and Yodoi J:
Identification of thioredoxin-binding protein-2/vitamin D(3)
up-regulated protein 1 as a negative regulator of thioredoxin
function and expression. J Biol Chem. 274:21645–21650. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masaki S, Masutani H, Yoshihara E and
Yodoi J: Deficiency of thioredoxin binding protein-2 (TBP-2)
enhances TGF-β signaling and promotes epithelial to mesenchymal
transition. PLoS One. 7:e399002012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Woolston CM, Madhusudan S, Soomro IN, Lobo
DN, Reece-Smith AM, Parsons SL and Martin SG: Thioredoxin
interacting protein and its association with clinical outcome in
gastro-oesophageal adenocarcinoma. Redox Biol. 1:285–291. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jung H, Kim MJ, Kim DO, Kim WS, Yoon SJ,
Park YJ, Yoon SR, Kim TD, Suh HW, Yun S, et al: TXNIP maintains the
hematopoietic cell pool by switching the function of p53 under
oxidative stress. Cell Metab. 18:75–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou J, Yu Q and Chng WJ: TXNIP (VDUP-1,
TBP-2): A major redox regulator commonly suppressed in cancer by
epigenetic mechanisms. Int J Biochem Cell Biol. 43:1668–1673. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwon HJ, Won YS, Suh HW, Jeon JH, Shao Y,
Yoon SR, Chung JW, Kim TD, Kim HM, Nam KH, et al: Vitamin D3
upregulated protein 1 suppresses TNF α induced NF-κB activation in
hepatocarcinogenesis. J Immunol. 185:3980–3989. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cadenas C, Franckenstein D, Schmidt M,
Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M,
Schumann A, et al: Role of thioredoxin reductase 1 and thioredoxin
interacting protein in prognosis of breast cancer. Breast Cancer
Res. 12:R442010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu G, Zhou L, Liu H, Shan Y and Zhang X:
MicroRNA-224 promotes pancreatic cancer cell proliferation and
migration by targeting the TXNIP-mediated HIF1α Pathway. Cell
Physiol Biochem. 48:1735–1746. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feingold PL, Surman DR, Brown K, Xu Y,
McDuffie LA, Shukla V, Reardon ES, Crooks DR, Trepel JB, Lee S, et
al: Induction of thioredoxin-interacting protein by a histone
deacetylase inhibitor, entinostat, is associated with DNA damage
and apoptosis in esophageal adenocarcinoma. Mol Cancer Ther.
17:2013–2023. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sheth SS, Bodnar JS, Ghazalpour A,
Thipphavong CK, Tsutsumi S, Tward AD, Demant P, Kodama T, Aburatani
H and Lusis AJ: Hepatocellular carcinoma in Txnip-deficient mice.
Oncogene. 25:3528–3536. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Yue Z, Xiong W, Sun P, You K and
Wang J: TXNIP overexpression suppresses proliferation and induces
apoptosis in SMMC7221 cells through ROS generation and MAPK pathway
activation. Oncol Rep. 37:3369–3376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen L, O'Shea JM, Kaadige MR, Cunha S,
Wilde BR, Cohen AL, Welm AL and Ayer DE: Metabolic reprogramming in
triple-negative breast cancer through Myc suppression of TXNIP.
Proc Natl Acad Sci USA. 112:5425–5430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han SH, Jeon JH, Ju HR, Jung U, Kim KY,
Yoo HS, Lee YH, Song KS, Hwang HM and Na YS: VDUP1 upregulated by
TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth
by blocking cell-cycle progression. Oncogene. 22:4035–4046. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morrison JA, Pike LA, Sams SB, Sharma V,
Zhou Q, Severson JJ, Tan AC, Wood WM and Haugen BR: Thioredoxin
interacting protein (TXNIP) is a novel tumor suppressor in thyroid
cancer. Mol Cancer. 13:622014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ikarashi M, Takahashi Y, Ishii Y, Nagata
T, Asai S and Ishikawa K: Vitamin D3 up-regulated protein 1 (VDUP1)
expression in gastrointestinal cancer and its relation to stage of
disease. Anticancer Res. 22:4045–4048. 2002.PubMed/NCBI
|
|
21
|
Park JW, Lee SH, Woo GH, Kwon HJ and Kim
DY: Downregulation of TXNIP leads to high proliferative activity
and estrogen-dependent cell growth in breast cancer. Biochem
Biophys Res Commun. 498:566–572. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nie W, Huang W, Zhang W, Xu J, Song W,
Wang Y, Zhu A, Luo J, Huang G, Wang Y and Guan X: TXNIP interaction
with the Her-1/2 pathway contributes to overall survival in breast
cancer. Oncotarget. 6:3003–3012. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang G, Zhang ZJ, Jian WG, Liu PH, Xue W,
Wang TD, Meng YY, Yuan C, Li HM, Yu YP, et al: Novel long noncoding
RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell
renal cell carcinoma proliferation via the Wnt β-catenin signaling
pathway. Mol Cancer. 18:152019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong B, Zhou J, Ma K, Zhang J, Xie H,
Zhang K, Li L, Cai L, Zhang N, Zhang Z and Gong K: TRIB3 promotes
the proliferation and invasion of renal cell carcinoma cells via
activating MAPK signaling pathway. Int J Biol Sci. 15:587–597.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Syed V: TGF-β Signaling in Cancer. J Cell
Biochem. 117:1279–1287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sitaram RT, Mallikarjuna P, Landstrom M
and Ljungberg B: Transforming growth factor-β promotes
aggressiveness and invasion of clear cell renal cell carcinoma.
Oncotarget. 7:35917–35931. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang HM, Noh KH, Chang TK, Park D, Cho HS
1, Lim JH and Jung CR: Ubiquitination of MAP1LC3B by pVHL is
associated with autophagy and cell death in renal cell carcinoma.
Cell Death Dis. 10:2792019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Fan Y, Huang S, Wang G, Han R,
Lei F, Luo A, Jing X, Zhao L, Gu S and Zhao X: Thymoquinone
inhibits the metastasis of renal cell cancer cells by inducing
autophagy via AMPK/mTOR signaling pathway. Cancer Sci.
109:3865–3873. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang ZL, Deng Q, Chong T and Wang ZM:
Autophagy suppresses the proliferation of renal carcinoma cell. Eur
Rev Med Pharmacol Sci. 22:343–350. 2018.PubMed/NCBI
|
|
30
|
Shang D, Liu Y, Ito N, Kamoto T and Ogawa
O: Defective Jak-Stat activation in renal cell carcinoma is
associated with interferon-alpha resistance. Cancer Sci.
98:1259–1264. 2007. View Article : Google Scholar : PubMed/NCBI
|
